Ascletis Pharma Inc. (1672) completed the placing of 69,256,000 new shares at HK$12.18 per share on February 10, 2026. The transaction raised gross proceeds of approximately HK$843.5 million, while net proceeds are estimated at around HK$835.2 million. According to the announcement, 90% of the net proceeds are allocated for preparation, groundwork, and the launch of global Phase III clinical trials of the small molecule oral GLP-1 receptor agonist ASC30 for obesity treatment, and 10% for working capital and other general corporate purposes.

Prior to the share placement, the company had 991,874,320 issued shares (excluding treasury shares). After completion of the placement, total issued shares (excluding treasury shares) rose to 1,061,130,320, representing an increase of approximately 6.53%. Controlling shareholders now hold around 54.28% of the issued shares (down from 58.07%), while the new placees own 6.53%, and all remaining shareholders collectively hold 39.20% of the enlarged share capital.